ConcertAI Appoints Michael Myshrall as Chief Financial Officer, Strengthening Financial Leadership to Drive Growth in AI-Powered Healthcare and Life Sciences ConcertAI, a global leader in oncology generative and agentic artificial…
Ifinatamab Deruxtecan Receives Breakthrough Therapy Designation from FDA for Pretreated Extensive-Stage Small Cell Lung Cancer The oncology research landscape took a significant step forward this week with the announcement that…
Grove Biopharma to Showcase Breakthrough Bionic Biologics™ at ACS Fall 2025 Symposium on Materials Biology Grove Biopharma, a private biotechnology company advancing an innovative therapeutic approach it calls Bionic Biologics™,…
AstraZeneca Launches FluMist Home: First Nationwide At-Home Delivery Service for Needle-Free Influenza Vaccination AstraZeneca has announced the launch of FluMist Home, a pioneering direct-to-consumer initiative that will allow individuals and…
RenovoRx Reports Strong Q2 2025 Revenue Growth and Receives Positive Independent Committee Recommendation to Continue Phase III TIGeR-PaC Trial RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage life sciences company pioneering targeted…
Omeros Corporation Reports Second Quarter 2025 Financial Results, Advances Narsoplimab Regulatory Reviews, and Strengthens Balance Sheet Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company dedicated to developing novel therapeutics for serious…
ScaleReady Awards $300,000 G-Rex® Grant to Gates Institute’s Translational Sciences Laboratory to Advance Modular CAR T-Cell Manufacturing ScaleReady, a joint venture formed by Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady,…
Scholar Rock Announces Landmark Lancet Neurology Publication of Pivotal Phase 3 SAPPHIRE Trial Results for Apitegromab in Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to…
Nu-Tek BioSciences to Showcase 100% Animal-Free Peptones and Yeast Extracts at BPI East 2025, Driving the Future of Sustainable Cell Culture and Fermentation In an era where biopharmaceutical manufacturers are…
Cybin Announces Major Clinical and Regulatory Milestones Alongside First Quarter Fiscal Year 2026 Financial Results Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN), a clinical-stage breakthrough neuropsychiatry company focused on…
Alto Neuroscience Appoints Raymond Sanchez, M.D., to Board of Directors, Strengthening Leadership as Company Advances Late-Stage Precision Psychiatry Pipeline Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company pioneering…
Innoviva Specialty Therapeutics Earns Dual Nominations for 2025 Prix Galien USA Best Pharmaceutical Product Award for ZEVTERA® and XACDURO® Innoviva Specialty Therapeutics, a wholly owned subsidiary of Innoviva, Inc. (NASDAQ:…